

MEMENİN MEZENKİMAL TÜMÖRLERİ

Hamide SAYAR¹

Vasküler tümörler

- Hemanjiom
- Anjiomatozis
- Atipik vasküler lezyon
- Memenin postradyasyon anjiosarkomu
- Memenin primer anjiosarkomu

Fibroblastik/myofibroblastik tümörler

- Nodüler fasiit
- Myofibroblastom
- Desmoid fibromatozis
- İnflamatuar myofibroblastik tümör

Periferik sinir kılıfı tümörü

- Schwannom
- Nörofibrom
- Granüler hücreli tümör

Düz kas tümörleri

- Leiomyom
- Leiomyosarkom

Adipositik tümörler

- Lipom
- Anjiolipom
- Liposarkom

Diğer mezenkimal tümörler ve tümör benzeri lezyonlar

- Psödoanjiomatöz stromal hiperplazi

GİRİŞ

Vücutun farklı lokalizasyonlarında karşılaştığımız benign ve malign mezenkimal lezyonlar memede de tanımlanmıştır. Kitabın bu bölümünde tüm mezenkimal lezyonlardan ziyade daha sık görülen veya ayırcı tanı açısından önemli olan lezyonlar tartışılacaktır. Memede yumuşak doku sarkomlarının insidansı bir milyonda 30-50 vaka civarındadır, aslında nadir görülmektedir. Benign yumuşak doku neoplazilerinin insidansı ise 100 kat daha yüksektir. Mezenkimal neoplaszi ile karşılaşlığımızda öncelikle lezyonun benign olma ihtimalinden başlayıp, anaplasti kriterlerini dikkatli gözden geçirdikten sonra malign tanısına yönelmeliyiz. Çoğu yumuşak doku neop-

¹ Doç.Dr, Tıbbi Patoloji, Mersin Üniversitesi Hastanesi, hamide1976@yahoo.com

KAYNAKÇA

1. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ, eds. WHO Classification of Tumours of the Breast. 5th ed. IARC, Lyon; 2019. ISBN.13; p188-230.
2. Rosen PP. Rosen's Breast Pathology. 4rd ed. Lipincott Williams & Wilkins, Lyon, France; 2009. P1019-1165.
3. Howitt B, Nascimento AF. Vascular Lesions of the Breast. *Surg Pathol Clin.* 2012 ;5(3):645-59.
4. Nagar H, Marmor S, Hammar B. Haemangiomas of the breast in children. *Eur J Surg.* 1992 ;158(9):503-5.
5. Yoga A, Lyapichev KA, Baek D, et al. Hemangio-
ma of a Male Breast: Case Report and Review of the Literature. *Am J Case Rep.* 2018;30;19:1425-1429.
6. Farid M. Essentials of Diagnostic Breast Pathology, Practical Approach. 1st ed. Berlin: Springer; 2007. ISBN 978-3-540-45117-4.
7. Branton PA, Lininger R, Tavassoli FA. Papillary endothelial hyperplasia of the breast: the great impostor for angiosarcoma. A clinicopathologic review of 17 cases. *Int J Surg Pathol* 2003;11:83-7.
8. Ginter PS, McIntire PJ, Irshaid L, et al. Angiomatosis of the breast: a clinicopathological and immunophenotypical characterisation of seven cases. *J Clin Pathol.* 2019;72(9):597-602.
9. Natsiopoulos I, Liappis T, Demin E, et al. Diffuse breast angiomyomatosis with involvement of overlying skin: a case report. *Clin Breast Cancer.* 2016;16(1):7-10.
10. Ciurea A, Dudea SM, Lebovici A, et al. Diffuse angiomyomatosis of the breast sonographic appearance. *J Clin Ultrasound.* 2014;42(8):498-501.
11. Morrow M, Berger D, Thelmo W. Diffuse cystic angiomyomatosis of the breast. *Cancer* 1988;1:62(11):2392-6.
12. Ginter PS, McIntire PJ, Shin SJ. Vascular tumours of the breast a comprehensive review with focus on diagnostic challenges encountered in the core biopsy setting. *Pathology.* 2017;49(2):197-214.
13. Sanz-Motilva V, Martorell-Calatayud A, Rongioletti F, et al. Diffuse dermal angiomyomatosis of the breast: clinical and histopathological features. *Int J Dermatol.* 2014;53(4):445-9.
14. Mekhail Y, Prather A, Hanna C, et al. Focal angiomyomatosis of the breast with MRI and histologic features. *Radiol Case Rep.* 2017;18;12(2):219-22.
15. Brenn T, Fletcher CD. Radiation associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. *Am J Surg Pathol.* 2005;29(8):983-96.
16. Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. *Am J Surg Pathol.* 2008;32(6):943-50.
17. Ginter PS, Mosquera JM, MacDonald TY, et al. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. *Hum Pathol.* 201;45(4):709-16.
18. Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. *Am J Surg Pathol.* 2004;28(6):78.
19. Seo IS, Min KW. Postirradiation epithelioid angiosarcoma of the breast: a case report with immunohistochemical and electron microscopic study. *Ultrastruct Pathol.* 2003;27(3):197-203.
20. Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. *Am J Surg Pathol.* 2008;32(12):1896-904.
21. Folpe AL, Chand EM, Goldblum JR, et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. *Am J Surg Pathol.* 2001;25(8):1061-6.
22. Mentzel T, Schildhaus HU, Palmedo G, et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. *Mod Pathol.* 2012;25(1):7585.
23. Huang SC, Zhang L, Sung YS, et al. Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLG1, KDR, MYC, and FLT4 gene alterations. *Am J Surg Pathol.* 2016 May;40(5):645-55.
24. Hodgson NC, Bowen-Wells C, Moffat F, et al. Angiosarcomas of the breast: a review of 70 cases. *Am J Clin Oncol.* 2007;30:570-3.
25. Yin M, Wang W, Drabick JJ, et al. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. *BMC Cancer.* 2017 27:17(1);295
26. Paliogiannis P, Cossu A, Palmieri G, et al. Breast nodular fasciitis: a comprehensive review. *Breast Care (Basel).* 2016;11(4):270-4.
27. Krings G, McIntire P, Shin SJ. Myofibroblastic, fibroblastic and myoid lesions of the breast. *Semin Diagn Pathol.* 2017;34(5):427-437.
28. Schnitt SJ. Spindle cell lesions of the breast. *Surg Pathol Clin.* 2009;2(2):375-90.

29. Kumar E, Patel NR, Demicco EG, et al. Cutaneous nodular fasciitis with genetic analysis: a case series. *J Cutan Pathol.* 2016;43(12):1143-9.
30. Magro G, Righi A, Casorzo L, et al. Mammary and vaginal myofibroblastomas are genetically related lesions: fluorescence in situ hybridization analysis shows deletion of 13q14 region. *Hum Pathol.* 2012;1887-93.
31. Magro G. Mammary myofibroblastoma: a tumor with a wide morphologic spectrum. *Arch Pathol Lab Med.* 2008;132(11):1813-20.
32. Magro G. Mammary myofibroblastoma: an update with emphasis on the most diagnostically challenging variants. *Histol – Histopathol.* 2016;31(1):1-23.
33. Devouassoux-Shisheboran M, Schammel MD, Man YG, et al. Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. *Arch Pathol Lab Med* 2000;124(2):276-80.
34. Wargotz ES, Norris HJ, Austin RM, et al. Fibromatosis of the breast, A clinical and pathological study of 28 cases. *Am J Surg Pathol.* 1987;11(1):38-45.
35. Neuman HB, Brogi E, Ebrahim A, et al. References 333 Desmoid tumors (fibromatoses) of the breast: a 25-year experience. *Ann Surg Oncol.* 2008;15(1):274-80.
36. Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis, *Genes Chromosomes Cancer.* 2015;54(10):606-15.
37. Pickett JL, Chou A, Andrici JA, et al. Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required. *Am J Surg Pathol.* 2017;41(10):1433-42.
38. Khanafshar E, Phillipson J, Schammel DP, et al. Inflammatory myofibroblastic tumor of the breast. *Ann Diagn Pathol.* 2005;9(3):123-9.
39. Charu V, Cimino-Mathews A. Peripheral nerve sheath tumors of the breast. *Semin Diagn Pathol* 2017;34(5):420-426.
40. Kamilaris CDC, Faucz FR, Voutetakis A, et al. Carney Complex. *Exp Clin Endocrinol Diabetes.* 2019;127(2-03):156-164.
41. Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. *Oncogene.* 2016;35(5):537-48.
42. Torres-Mora J, Dry S, Li X, et al. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma". *Am J Surg Pathol.* 2014;38(1):94-105.
43. Jeyaretna DS, Oriolowo A, Smith ME, et al. Solitary neurofibroma in the male breast. *World J Surg Oncol.* 2007;27:5:23.
44. McClatchey AI. Neurofibromatosis. *Annu Rev Pathol* 2007;2:191-21645-Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. *Hum Pathol.* 2017;67:1-10.
45. Adeniran A, Al-Ahmadie H, Mahoney MC, et al. Granular cell tumor of the breast: a series of 17 cases and review of the literature. *Breast J.* 2004;10(6):528-31
46. Fanburg-Smith JC, Meis-Kindblom JM, Fante R, et al. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. *Am J Surg Pathol.* 1998;22(7):779-94
47. Pareja F, Brandes AH, Basili T, et al. Loss-of-function mutations in ATPGAP1 and ATPGAP2 in granular cell tumors. *Nat Commun.* 2018;30;9(1):3533.
48. Pérez-González YC, Pagura L, Llamas-Velasco M, et al. Primary cutaneous malignant granular cell tumor: an immunohistochemical study and review of the literature. *Am J Dermatopathol.* 2015;37(4):334-40.
49. Sekimizu M, Yoshida A, Mitani S, et al. Frequent mutations of genes encoding vacuolar H+-ATPase components in granular cell tumors. *Genes Chromosomes Cancer.* 2019;58(6):373-80.
50. Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss' Soft Tissue Tumors. 7th ed. Philadelphia, PA: Mosby Elsevier; 2020:944.
51. Fanburg-Smith JC, Meis-Kindblom JM, Fante R, et al. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. *Am J Surg Pathol.* 1998;22:779–794.
52. Carter CS, Skala SL, Chinnaian AM, et al. Immunohistochemical characterization of fumarate hydratase (FH) and succinate dehydrogenase (SDH) in cutaneous leiomyomas for detection of familial cancer syndromes. *Am J Surg Pathol.* 2017;41(6):801-9.
53. Ende L, Mercado C, Axelrod D, et al. Intraparenchymal leiomyoma of the breast: a case report and review of the literature. *Ann Clin Lab Sci.* 2007;37(3):268-73.
54. Hussien M, Sivananthan S, Anderson N, et al. Primary leiomyosarcoma of the breast: diagnosis, management and outcome. A report of a new case and review of literature. *Breast* 2001;10(6):530-4.
55. Beck AH, Lee CH, Witten DM, et al. Discovery of molecular subtypes in leiomyosarcoma throu-

- gh integrative molecular profiling. *Oncogene*. 2010;11;29(6):845-54.
56. Falconieri G, Della Libera D, Zanconati F, et al. Leiomyosarcoma of the female breast: report of two new cases and a review of the literature. *Am J Clin Pathol*. 1997;108(1):19-25.
 57. Tajima S, Koda K, Fukayama. Primary leiomyosarcoma of the breast with prominent osteoclastic giant cells: A case expressing receptor activator of NF-kappaB ligand (RANKL). *M.Pathol Int*. 2015 Jul 7. doi: 10.1111/pin.12328
 58. Lanng C, Eriksen B Ø, Hoffmann J. Lipoma of the breast a diagnostic dilemma. *Breast*. 2004;13(5):408-11.
 59. Li YF, Lv MH, Chen LF, et al. Giant lipoma of the breast: a case report and review of the literature. *Clin Breast Cancer* 201;11(6):420-2.
 60. Shintaku M, Yamamoto Y, Kono F, et al, Chondrolipoma of the breast as a rare variant of myofibroblastoma: an immunohistochemical study of two cases. *Virchows Arch*. 2017;471(4):531-5.
 61. Hofvander J, Arbajian E, Stenkula KG, et al. Frequent low-level mutations of protein kinase D2 in angiolioma. *J Pathol* 2017;241(5):578-8263- Baker GM, Schnitt SJ. Vascular lesions of the breast. *Semin Diagn Pathol*. 2017;34(5):410-9.
 62. Kryvenko ON, Chitale DA, VanEgmond EM, et al. Angiolipoma of the female breast: clinicopathological correlation of 52 cases. *Int J Surg Pathol*. 2011 Feb;19(1):35-43.
 63. Briski LM, Jorns JM. Primary Breast Atypical Lipomatous Tumor/Well Differentiated Liposarcoma and Dedifferentiated Liposarcoma. *Arch Pathol Lab Med*. 2018 Feb;142(2):268-274.
 64. Adem C, Reynolds C, Ingle JN, et al. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. *Br J Cancer*. 200;91(2):237-241.
 65. Sreekantaiah C, Karakousis CP, Leong SP, et al. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. *Cancer*. 1992;15;69(10):2484-95.
 66. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature*. 1993;17:363(6430):640-4.
 67. Marimo-Enriquez - A, Fletcher CD, Dal Cin P, et al. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. *Am J Surg Pathol*. 2010;34(8):1122-31.
 68. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. *Ann Surg* 2006;244(3):381-91.
 69. Saito T, Ryu M, Fukumura Y, et al. A case of myxoid liposarcoma of the breast. *Int J Clin Exp Pathol*. 2013;15;6(7):1432-6.
 70. Hornick JL, Bosenberg MW, Mentzel T, et al. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. *Am J Surg Pathol*. 2004;28(10): 1257-67.
 71. Raj SD, Sahani VG, Adrada BE, et al. Pseudoangiomatous stromal hyperplasia of the breast: multimodality review with pathologic correlation. *Curr Probl Diagn Radiol*. 2017;46(2):130-5.
 72. Virk RK, Khan A. Pseudoangiomatous stromal hyperplasia: an overview. *Arch Pathol Lab Med* 2010;134(7):1070-4.
 73. Nassar H, Elieff MP, Kronz JD, et al. Pseudoangiomatous - stromal – hyperplasia (PASH) of the breast with foci of morphologic malignancy: a case of PASH with malignant transformation? *Int J Surg Pathol*. 2010;18(6):564-9.
 74. Magro G. Differential Diagnosis of Benign Spindle Cell Lesions. *Surg Pathol Clin*. 2018;11(1):91-121.